Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/25 mg, 30-count bottles, lot. Nos. 21x006, expiration 11/2018 and 21x007, expiration 2/2019.
PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA today confirmed a voluntary recall to the consumer / user level of 29 lots of single and 51 lots of combination valsartan medicines ...
HERTFORDSHIRE, England and PITTSBURGH, Dec. 4, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level ...
This study was a randomized, double-blind, parallel-group, active-control trial conducted in 15 countries. The study design, patient selection criteria and disposition of all patients enrolled were ...
A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". HERTFORDSHIRE, England and PITTSBURGH, Nov. 20, 2018 /PRNewswire/ -- Mylan ...
Several common drugs that contain valsartan, used to treat high blood pressure and heart failure, have been recalled in the United States due to an "impurity" in the drug that poses a potential cancer ...
The main purpose of the two open, non-comparative PMS studies reported here was to extend the knowledge base of the efficacy and tolerability of once-daily valsartan (trial 1) and the fixed ...
A week after two more blood pressure drugs were recalled because they have a possible cancer-causing ingredient, the U.S. based Mylan Pharmaceuticals expanded its consumer-level voluntary nationwide ...
Concomitant therapy with the following medications was prohibited: other ARBs, angiotensin-converting enzyme (ACE) inhibitors, β-adrenergic antagonists, calcium-channel blockers, any other ...
Teva Pharmaceuticals has launched a voluntary recall into two drugs used to treat high blood pressure as yet more medications face concerns over a possible cancer risk. In a statement from Teva posted ...
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/6kgr9m/investigation) has announced the addition of the "Investigation ...
General practitioners throughout Germany were invited to participate in two open-label, noncomparative PMS studies, performed in accordance with the guidelines of German Drug Law (AMG). The reporting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback